Search parameters included the following: MS: database: NCBInr; taxonomy: Homo sapiens; enzyme: trypsin; missed cleavages allowed: 1; fixed modifications: none; protein mass: not specified; peptide tolerance: G1.2 kDa; mass values: MHC; monoisotopic/average: monoisotopic; MS/MS: database: NCBInr; taxonomy: H. (two isoforms). One protein spot, identified as complement C4B precursor, was increased after the surgery. == Conclusions == Seven serum protein spots were differentially expressed following surgery in acromegalic patients. The identified proteins represent potential novel biomarkers to assess the effectiveness of surgical treatment in acromegalic individuals. Future studies will validate the use of the identified proteins as biomarkers of disease activity after medical treatment of acromegaly. == Introduction == GH is synthesized and released by somatotropic cells in the anterior lobe of the pituitary gland (1). Abnormal GH secretion leads to impairments in growth and metabolic processes (24). Acromegaly is an endocrine disorder, usually the consequence of a GH producing pituitary adenoma (1), characterized by elevated serum levels of GH and insulin-like growth factor 1 (IGF1) (1,5). If left untreated or poorly controlled, premature mortality ensues caused mainly from cardiovascular diseases (68). EBI-1051 The primary treatment for acromegaly remains transsphenoidal surgery (9,10). GH-secreting microadenomas are Mouse monoclonal to CK17 usually successfully removed by surgery, whereas the outcome is less favorable with larger tumors (1113). Assessment of the surgical outcome is therefore important, but no ideal biomarker is currently available (14). Moreover, discrepant results of serum GH and IGF1 levels, i.e. elevated GH and normal IGF1 or vice versa, are often observed (1416). Thus, the absence of totally reliable biochemical markers of acromegaly makes the evaluation of the treatment outcome difficult. In this study, experiments were performed to identify serum biomarkers associated with acromegaly before and after transsphenoidal adenomectomy. The serum samples were analyzed using a two-dimensional gel electrophoresis (2DE) proteomic approach and western blotting. Seven proteins displayed significant changes after surgery. These proteins represent biomarkers to evaluate the outcomes of surgical treatment of acromegalic patients. Moreover, results similar EBI-1051 to ours reveal potential GH-responsive proteins that EBI-1051 could be used to develop assays for the detection of GH in clinical and sporting (doping) scenarios. == Materials and methods == == Subjects and serum samples (performed at Aarhus University Hospital, Aarhus, Denmark) == Eight acromegalic patients (three females and five males) were included in this study and were 2671 years of age (mean ageZ51 years). All patients presented with classic symptoms and signs of acromegaly including the presence of a pituitary adenoma visualized by magnetic resonance imaging. All patients were treated with surgery alone, i.e. none of the patients had received dopamine agonists, somatostatin analogs, or the GH receptor antagonist, pegvisomant, at any time point, and no patient had received radiation therapy. Serum samples were obtained before and 36 months after transsphenoidal surgery. The patients were hospitalized the day before and blood was drawn the following morning in the fasting state and during an oral load of glucose (75 g). After incubation for 3060 min at room temperature, the samples were centrifuged at 3500 g for 10 min at 4 8C. Serum was removed and stored at K20 8C for an interval of 14 years. All subjects gave a written informed consent before participating in the study, which was approved by The Central Denmark Region Committees on Biomedical Research Ethics (200401184) in adherence to the Declaration of Helsinki. The protocol was also approved by the Ohio University Institutional Review Board. == GH, IGF1, and total haptoglobin measurements (performed at Aarhus University Hospital) == Serum GH was measured by a DELFIA assay (Perkin-Elmer, Trku, Finland) and serum IGF1 levels were determined by an in-house noncompetitive, time-resolved immunofluorometric assay. Both assays have been previously described (17). Total haptoglobin levels were determined by Cobas c-systems (Roche Diagnostics), in short, human haptoglobin was precipitated with a specific antiserum and the turbidity was estimated. The method had a detection range of 0.15.7 g/l (or 1.057 mmol/l) and had a reproducibility of 0.71.3 coefficient of variation %. == Sample preparation for proteomic analysis (performed at Ohio University, Athens, OH, USA) == Serum samples were shipped frozen on dry ice from Aarhus, Denmark to Athens, Ohio. Upon arrival, samples were stored frozen at K80 8C for 3 weeks until further analysis. In general, all proteomic procedures were performed as described previously (1821). Briefly, serum protein concentrations were determined by the Bradford method. No significant difference in total protein concentration was found between the samples obtained pre- and post-surgery (PO0.05 in a paired t-test). Albumin depletion of the samples was.